The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide

The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide

Objective/Background: Pyrazinamide (PZA) is an antibacterial used in the first-line regimen against tuberculosis (TB) for its action against dormant bacilli. PZA is also included in the new short regimen to treat multidrug-resistant TB (MDR-TB). However, the prevalence and significance of PZA resist...

Full description

Bibliographic Details
Main Authors: Géraldine Daneau, Mourad Gumusboga, Pim De Rijk, Arnaud Trebucq, Leen Rigouts, Armand Van Deun, Bouke C de Jong
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:International Journal of Mycobacteriology
Subjects:
MDR-TB
Mutation
pncA
Pyrazinamide (PZA)
Resistance
Tuberculosis
Online Access:http://www.ijmyco.org/article.asp?issn=2212-5531;year=2016;volume=5;issue=5;spage=46;epage=47;aulast=Daneau

Internet

http://www.ijmyco.org/article.asp?issn=2212-5531;year=2016;volume=5;issue=5;spage=46;epage=47;aulast=Daneau

Similar Items